Blood test may spot ovarian cancer return months before scans

NCT ID NCT07670962

Not yet recruiting Diagnosis Sponsor: Asan Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a specialized blood test can detect tiny bits of cancer DNA in the blood of women with advanced ovarian cancer after they finish initial treatment. Researchers will follow 300 women for up to 3 years, taking blood samples at key times. The goal is to see if the test can predict cancer recurrence earlier than standard imaging or blood tests.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Blood-based ctDNA minimal residual disease (MRD) test
What this could lead to: If successful, this blood test could help doctors identify which patients are at high risk of their ovarian cancer returning, potentially allowing earlier intervention.
What could go wrong: This is an observational study, not a treatment trial. The test may not accurately predict recurrence for all patients, and results may not change outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, OVARIAN EPITHELIAL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Carcinoma, Ovarian Epithelial Neoplasm, Residual ovarian cancer ovarian carcinoma ovarian epithelial tumor ovarian neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, OVARIAN EPITHELIAL OVARIAN CANCER OVARIAN NEOPLASMS

More trials for these conditions

Other studies related to the condition(s) this trial covers.